Dimerix Ltd has released a press release.
ACTION3 IND Approved in China
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Dimerix
- Dimerix Receives Initial Upfront Payment from Advanz Pharma
- Dimerix Announces License Agreement for EU, Canada, ANZ
- FDA Approves Qytovra Brand Name
- Regulatory Approval received in Malaysia for ACTION3 Study
- Dimerix Receives $8.9M R&D Tax Incentive Rebate
Later from Dimerix
- Half-Year Financial Report & Appendix 4D - 31 December 2023
- PH3 Data Collection Complete for First Interim Analysis
- Dimerix Successfully Passes Efficacy Interim Analysis
- Dimerix Completes $20M Placement
- Dimerix Receives PIP Approval from the UK MHRA
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix